Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 18, 2024

NCCN Guidelines Revisions and ASCO 2024 Research Outlook

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

Episodes in this series

Patient with breast cancer takes medicine - Image Credit: Seventyfour - stock.adobe.com

EP. 1 NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer

1 KOL is featured in this series.

EP. 2 Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024

1 KOL is featured in this series.

EP. 3 Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

1 KOL is featured in this series.

EP. 4 Tailoring CDK4/6 Inhibitor Treatment to Patient Needs

1 KOL is featured in this series.

EP. 5 NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib

1 KOL is featured in this series.

EP. 6 Exploring Results from CAPItello-291 Trial

1 KOL is featured in this series.

EP. 7 Exploring Biomarker Testing and Personalized Treatments in Breast Cancer

1 KOL is featured in this series.

EP. 8 NCCN Guidelines Revisions and ASCO 2024 Research Outlook

1 KOL is featured in this series.

EP. 9 Emerging Breast Cancer Therapies and Closing Thoughts

How do you think the revised NCCN Guidelines for breast cancer will impact patient outcomes?
What data, results, or insights are you looking forward to coming out of ASCO 2024?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Kevin Kaiserman, MD

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD

ByGiuliana Grossi,Kevin Kaiserman, MD

June 5th 2026

Rising piles of coins indicating cost savings | Image credit: THAWEERAT - stock.adobe.com

Delgocitinib Coverage Could Save Health Plans $88M Over 3 Years

ByLaura Joszt, MA

June 5th 2026

Noah Greenspan, DPT

COVID Postexposure Prophylaxis Expands Prevention Toolkit: Noah Greenspan, DPT, PT

BySabrina McCrear,Noah Greenspan, DPT, PT, CCS, EMT-B

June 5th 2026

Doctor writes a script for asthma. | Image credit: @Goffkein - stock.adobe.com

SUNRISE Trial: Tezepelumab Reduces Steroid Use in Severe Asthma

BySabrina McCrear

June 5th 2026

tryptophan and nuts | Image credit: Danijela - stock.adobe.com

Disrupted Tryptophan Metabolism Linked to Psoriasis Severity, Multiple Comorbidities

BySkylar Jeremias

June 5th 2026

Trending on AJMC

Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention

INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD

First FDA-Approved Inhaled Insulin for Kids Arrives With Mounting Data: Kevin Kaiserman, MD

COVID Postexposure Prophylaxis Expands Prevention Toolkit: Noah Greenspan, DPT, PT

AI Reshaping Diabetes Care From Nutrition to Clinical Decisions